Volenrelaxin (LY3540378) increases Renal Plasma Flow: A Randomized Phase 1 Trial.

Lai San ThamHiddo J Lambers HeerspinkXiaojun WangPetra VerdinoChadi G SaifanEric A BensonPaul GoldsmithZhenzhong WangJeffrey M TestaniAxel HauptFlora SamDavid Z I Cherney

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)

Volenrelaxin was well-tolerated, safe and suitable for weekly SC dosing. Volenrelaxin showed a sustained improvement in kidney perfusion upon repeated dosing, supporting further clinical development in chronic kidney disease and chronic heart failure. Clinical trial registration: NCT04768855.

Keyphrases

clinical trial
ejection fraction
phase ii
open label
study protocol
double blind
magnetic resonance imaging
phase iii